Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Liberty Global Ltd Class CTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Liberty Global Ltd Class C — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9 (market cap $590.53M), while Liberty Global Ltd Class C trades at $10.46 (market cap $3.59B). The key difference: Liberty Global Ltd Class C is far larger — about 6.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.

DNALBTYK
Market Cap
$590.53M$3.59B
Sector
HealthTechnology
52-Week High
$16.14$12.67
52-Week Low
$5.48$10.07
Enterprise Value
$627.78M$10.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.

The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.

Liberty Global Ltd Class C

LBTYK trades at $10.54, up 2.63% today, but technical indicators are bearish with a negative net income margin of -109.66% for 2026. The stock shows a low P/S of 0.71 and P/B of 0.37, indicating potential undervaluation. Recent news highlights the planned 2027 spin-off and Amsterdam listing of Ziggo Group as a key catalyst. Analyst consensus is strongly positive with 69% buy ratings, though earnings have been volatile with a significant miss in Q4 2025.

The outlook is mixed: the spin-off offers upside potential, but persistent losses and high debt pose risks. Investors should weigh the sum-of-the-parts valuation opportunity against operational challenges and market volatility. The stock remains speculative with a bearish technical trend despite positive analyst sentiment.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Liberty Global Ltd Class C

Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.

Read more on LBTYK